BioFIT Bucks!!
Paracelsian Announces Receipt of Initial International BioFIT(TM) Revenues
ITHACA, N.Y., April 12 /PRNewswire/ -- Paracelsian Inc. (OTCBB: PRLN - news) announced today that it has received the first revenues under its agreement with R.P. Scherer Limited, of Swindon, England. The agreement covers the development and marketing of BioFIT(TM) Herbgels(TM), the first herbal products that are quality assured based on the BioFIT(TM) ''functional'' testing program.
''These initial revenues from outside North America confirm the substantial progress Paracelsian has made with R.P. Scherer on the BioFIT Herbgel program,'' said Bernie Landes, Paracelsian's President and CEO. ''This validates the worldwide strategy we adopted last summer when we established our partnership with R.P. Scherer,'' he added. ''We fully expect significant revenues to continue flowing from both the North American and Worldwide implementation of the BioFIT program,'' he concluded.
The BioFIT Certification Program provides a new, higher level of quality assurance for herbal products. Instead of relying on traditional analytical techniques to assure the presence of active or presumed active constituents of herbs, BioFIT tests finished products, in the form in which they are consumed, to assure a minimum level of activity in biological mechanisms associated with the herb's claimed benefits, answering the most important question in the minds of consumers...Does it work? No other herbal products in the market today are tested in this manner. A complete description of the BioFIT program can be found at Paracelsian's web site (http://www.paracelsian.com) .
Paracelsian is a unique biotechnology company whose business centers on the development and application of functional bioassays. These assays are used for Quality Assurance of herbs, botanicals and other dietary supplements, in the development of dietary supplement, OTC and pharmaceutical products, and in monitoring environmental toxins and identifying carcinogens. Notice: This news release may contain forward-looking statements.
|
